Neurosense Therapeutics Valuation
| NRSN Stock | USD 0.93 0.02 2.20% |
Today, the firm appears to be undervalued. Neurosense Therapeutics secures a last-minute Real Value of $2.45 per share. The latest price of the firm is $0.93. Our model forecasts the value of Neurosense Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 35.03 %, current valuation of 17.68 M, and Return On Equity of -4.95 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neurosense Therapeutics' valuation include:
Price Book 4.1496 | Enterprise Value 17.7 M | Enterprise Value Ebitda (1.16) |
Undervalued
Today
Please note that Neurosense Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Neurosense Therapeutics is based on 3 months time horizon. Increasing Neurosense Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurosense Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurosense Stock. However, Neurosense Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.93 | Real 2.45 | Target 7.25 | Hype 0.89 |
The intrinsic value of Neurosense Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neurosense Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neurosense Therapeutics helps investors to forecast how Neurosense stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurosense Therapeutics more accurately as focusing exclusively on Neurosense Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neurosense Therapeutics' intrinsic value based on its ongoing forecasts of Neurosense Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neurosense Therapeutics' closest peers.
Neurosense Therapeutics Cash |
|
Neurosense Valuation Trend
Knowing Neurosense Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Neurosense Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Neurosense Therapeutics Total Value Analysis
Neurosense Therapeutics is now projected to have valuation of 17.68 M with market capitalization of 19.26 M, debt of 142 K, and cash on hands of 10.37 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neurosense Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.68 M | 19.26 M | 142 K | 10.37 M |
Neurosense Therapeutics Asset Utilization
One of the ways to look at asset utilization of Neurosense is to check how much profit was generated for every dollar of assets it reports. Neurosense Therapeutics secures a negative usage of assets of -1.51 %, losing $0.0151 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Neurosense Therapeutics shows how discouraging it operates for each dollar spent on its assets.Neurosense Therapeutics Ownership Allocation
Neurosense Therapeutics maintains a total of 20.71 Million outstanding shares. Neurosense Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neurosense Therapeutics Profitability Analysis
Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0.About Neurosense Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Neurosense Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Neurosense Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Neurosense Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Neurosense Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurosense Therapeutics. We calculate exposure to Neurosense Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurosense Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -97 K | -92.2 K |
Neurosense Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 13.6 M |
Neurosense Therapeutics Current Valuation Indicators
Neurosense Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Neurosense Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neurosense Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neurosense Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neurosense Therapeutics' worth.When determining whether Neurosense Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurosense Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurosense Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurosense Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.